Scarica l'app Stockscreener
1.00
14.35%
-0.1675
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCLI Giù?
Forum
Previsione
Frazionamento azionario
Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie
Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions - Yahoo Finance
Brainstorm Cell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pitts Peter Joe - Moomoo
BrainStorm Cash Drops to $0.2 Million, Raising Going-Concern Risk - Minichart
Brainstorm Cell Therapeutics (BCLI) posts loss and warns on going concern - Stock Titan
BCLI: Phase 3b ALS trial preparations advance as net loss widens and new capital is secured - TradingView
BrainStorm Posts $3.9 Million Second-Quarter Net Loss as NurOwn Trial Preparations Continue - Quiver Quantitative
Brainstorm Cell Therapeutics | 8-K: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Lunai Bioworks signs collaboration with BrainStorm Therapeutics By Investing.com - Investing.com South Africa
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 - PR Newswire
Brainstorm Appoints Former FDA Associate Comm - Moomoo
BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial - TipRanks
Form 4 Brainstorm Cell Therapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria
BrainStorm Cell (BCLI) grants 100,000 RSUs to director Frenkel - Stock Titan
Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes - marketscreener.com
BrainStorm names ex-FDA official Pitts as executive chairman By Investing.com - Investing.com Canada
BrainStorm's ALS Trial Set to Launch Under First-Ever Special Protocol Assessment - Stock Titan
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman - Prime Publishers, Inc.
CYVNY Stock Price and Chart — OTC:CYVNY - TradingView
Peter Joe Pitts Net Worth (2026) - GuruFocus
Price to earnings forward of BrainStorm Cell Therapeutics Inc. – OTC:BCLI - TradingView
Price to earnings forward of Brainstorm Cell Therapeutics Inc. – SWB:GHD - TradingView
Brainstorm Cell Therapeutics (BCLI) Status Update Summary - Quartr
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Brainstorm Cell Therapeutics Inc. Actuals & Estimates (OTC:BCLI) - TradingView
Brainstorm Cell Therapeutics Inc (BCLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Institutional Confidence - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Brainstorm Cell Therapeutics Inc (BCLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Brainstorm Cell Therapeutics Inc - TradingKey
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
Brainstorm leaders urge FDA to update treatment review process - ALS News Today
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) Stock Price, Quote, News & History - Benzinga
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
The Escalator: VML Health, BrainStorm Cell Therapeutics, Syneos Health and more - Medical Marketing and Media
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant - Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing - Stock Titan
BrainStorm Cell Therapeutics Announces Publication Calling for U - GuruFocus
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - PR Newswire
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay - Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant - Stock Titan
Officer at Brainstorm Cell (NASDAQ: BCLI) awarded 100,000 RSUs - Stock Titan
BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award - Stock Titan
Brainstorm Cell (BCLI) director receives 120,000-share RSU award - Stock Titan
BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026 - marketscreener.com
Gene and Cell Therapies Targeting CNS Disorders Market - openPR.com
BrainStorm Adds Former FDA Leader to Board - TipRanks
Peter Pitts joins Brainstorm Cell (OTCQB: BCLI) board of directors - Stock Titan
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commi - GuruFocus
BrainStorm adds ex-FDA official to board ahead of ALS trial By Investing.com - Investing.com South Africa
BrainStorm adds ex-FDA official to board ahead of ALS trial - Investing.com Australia
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire
BCLI SEC FilingsBrainstorm Cell Therapeutics I 10-K, 10-Q, 8-K Forms - Stock Titan
7.8M Brainstorm (OTCQB: BCLI) shares registered for warrant-linked resale - Stock Titan
Brainstorm Cell Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
BrainStorm Cell (BCLI) director receives 150,000 stock options at $0.70 strike - Stock Titan
BrainStorm Cell (BCLI) director granted 150K options at $0.70 strike - Stock Titan
1.48%
0.31%
Capitalizzazione:
|
Volume (24 ore):